Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 311

1.

Open label study of inhaled aztreonam for Pseudomonas eradication in children with cystic fibrosis: The ALPINE study.

Tiddens HA, De Boeck K, Clancy JP, Fayon M, H G M A, Bresnik M, Derchak A, Lewis SA, Oermann CM; ALPINE study investigators.

J Cyst Fibros. 2015 Jan;14(1):111-9. doi: 10.1016/j.jcf.2014.06.003. Epub 2014 Aug 1.

2.

Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis.

McCoy KS, Quittner AL, Oermann CM, Gibson RL, Retsch-Bogart GZ, Montgomery AB.

Am J Respir Crit Care Med. 2008 Nov 1;178(9):921-8. doi: 10.1164/rccm.200712-1804OC. Epub 2008 Jul 24.

3.

Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis.

Retsch-Bogart GZ, Quittner AL, Gibson RL, Oermann CM, McCoy KS, Montgomery AB, Cooper PJ.

Chest. 2009 May;135(5):1223-1232. doi: 10.1378/chest.08-1421.

4.

An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis.

Oermann CM, Retsch-Bogart GZ, Quittner AL, Gibson RL, McCoy KS, Montgomery AB, Cooper PJ.

Pediatr Pulmonol. 2010 Nov;45(11):1121-34. doi: 10.1002/ppul.21301.

5.

Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine.

Elborn JS, Henig NR.

Expert Opin Pharmacother. 2010 Jun;11(8):1373-85. doi: 10.1517/14656566.2010.482102. Review.

PMID:
20426707
6.
7.

Aztreonam for inhalation solution (AZLI) in patients with cystic fibrosis, mild lung impairment, and P. aeruginosa.

Wainwright CE, Quittner AL, Geller DE, Nakamura C, Wooldridge JL, Gibson RL, Lewis S, Montgomery AB.

J Cyst Fibros. 2011 Jul;10(4):234-42. doi: 10.1016/j.jcf.2011.02.007. Epub 2011 Mar 26.

8.

Pseudomonas aeruginosa antibiotic susceptibility during long-term use of aztreonam for inhalation solution (AZLI).

Oermann CM, McCoy KS, Retsch-Bogart GZ, Gibson RL, McKevitt M, Montgomery AB.

J Antimicrob Chemother. 2011 Oct;66(10):2398-404. doi: 10.1093/jac/dkr303. Epub 2011 Jul 22.

PMID:
21784781
9.

Inhaled aztreonam lysine: an evidence-based review.

Hutchinson D, Barclay M, Prescott WA, Brown J.

Expert Opin Pharmacother. 2013 Oct;14(15):2115-24. doi: 10.1517/14656566.2013.831070. Epub 2013 Aug 31. Review.

PMID:
23992352
10.

Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.

Knudsen PK, Olesen HV, Høiby N, Johannesson M, Karpati F, Laerum BN, Meyer P, Pressler T, Lindblad A; Scandinavian CF Study Consortium (SCFSC).

J Cyst Fibros. 2009 Mar;8(2):135-42. doi: 10.1016/j.jcf.2008.11.001. Epub 2009 Jan 20.

11.

Inhaled aztreonam lysine for cystic fibrosis pulmonary disease-related outcomes.

Pesaturo KA, Horton ER, Belliveau P.

Ann Pharmacother. 2012 Jul-Aug;46(7-8):1076-85. doi: 10.1345/aph.1Q653. Epub 2012 Jul 3. Review.

PMID:
22764322
12.

Continuous alternating inhaled antibiotics for chronic pseudomonal infection in cystic fibrosis.

Flume PA, Clancy JP, Retsch-Bogart GZ, Tullis DE, Bresnik M, Derchak PA, Lewis SA, Ramsey BW.

J Cyst Fibros. 2016 Nov;15(6):809-815. doi: 10.1016/j.jcf.2016.05.001. Epub 2016 May 24.

PMID:
27233377
13.

The success of the different eradication therapy regimens for Pseudomonas aeruginosa in cystic fibrosis.

Emiralioglu N, Yalcin E, Meral A, Sener B, Dogru D, Ozcelik U, Kiper N.

J Clin Pharm Ther. 2016 Aug;41(4):419-23. doi: 10.1111/jcpt.12407. Epub 2016 Jun 16.

PMID:
27311742
14.

Comparison of two treatment regimens for eradication of Pseudomonas aeruginosa infection in children with cystic fibrosis.

Proesmans M, Vermeulen F, Boulanger L, Verhaegen J, De Boeck K.

J Cyst Fibros. 2013 Jan;12(1):29-34. doi: 10.1016/j.jcf.2012.06.001. Epub 2012 Jul 2.

15.

The effects of inhaled aztreonam on the cystic fibrosis lung microbiome.

Heirali AA, Workentine ML, Acosta N, Poonja A, Storey DG, Somayaji R, Rabin HR, Whelan FJ, Surette MG, Parkins MD.

Microbiome. 2017 May 5;5(1):51. doi: 10.1186/s40168-017-0265-7.

16.

Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial.

Assael BM, Pressler T, Bilton D, Fayon M, Fischer R, Chiron R, LaRosa M, Knoop C, McElvaney N, Lewis SA, Bresnik M, Montgomery AB, Oermann CM; AZLI Active Comparator Study Group.

J Cyst Fibros. 2013 Mar;12(2):130-40. doi: 10.1016/j.jcf.2012.07.006. Epub 2012 Sep 15.

17.

A phase 2 study of aztreonam lysine for inhalation to treat patients with cystic fibrosis and Pseudomonas aeruginosa infection.

Retsch-Bogart GZ, Burns JL, Otto KL, Liou TG, McCoy K, Oermann C, Gibson RL; AZLI Phase II Study Group.

Pediatr Pulmonol. 2008 Jan;43(1):47-58.

PMID:
18041081
18.

A network meta-analysis of the efficacy of inhaled antibiotics for chronic Pseudomonas infections in cystic fibrosis.

Littlewood KJ, Higashi K, Jansen JP, Capkun-Niggli G, Balp MM, Doering G, Tiddens HA, Angyalosi G.

J Cyst Fibros. 2012 Sep;11(5):419-26. doi: 10.1016/j.jcf.2012.03.010. Epub 2012 Jun 19.

19.

Patient-specific modeling of regional antibiotic concentration levels in airways of patients with cystic fibrosis: are we dosing high enough?

Bos AC, van Holsbeke C, de Backer JW, van Westreenen M, Janssens HM, Vos WG, Tiddens HA.

PLoS One. 2015 Mar 3;10(3):e0118454. doi: 10.1371/journal.pone.0118454. eCollection 2015.

20.

Aztreonam lysine: a novel inhalational antibiotic for cystic fibrosis.

Parkins MD, Elborn JS.

Expert Rev Respir Med. 2010 Aug;4(4):435-44. doi: 10.1586/ers.10.48. Review.

PMID:
20658904

Supplemental Content

Support Center